Business Wire

Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI® (pixantrone) from CTI BioPharma, strengthening the Servier oncology portfolio

Share

Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. Servier and CTI Biopharma completed an Asset Purchase Agreement which transferred worldwide rights of PIXUVRI to Servier. Servier commercialized PIXUVRI globally, in all countries where the drug was approved under an exclusive license from CTI BioPharma.

“The acquisition of PIXUVRI is an important step towards Servier’s long-term strategy to become a key player in oncology. Within oncology, one of our key focuses is hematology, and we now have two medicines that are marketed globally alongside a strong and innovative pipeline of drug candidates which includes CAR-T therapies,” said Claude Bertrand, Executive VP, Global Head of R&D at Servier. “As part of our strategy, we are committed to invest 50% of our R&D budget in oncology.”

Non-Hodgkin lymphoma (NHL) is a blood cancer that affects the lymphatic system, it can occur in different parts of the body from the lymph nodes in the neck to the liver or spleen, but also in other organs such as the stomach, small bowel, bones, brain, testicles or skin.1 Globally there are over 500,000 new cases of NHL a year; it is both the 11th most commonly diagnosed cancer and cause of cancer death.2

“We have a strong commitment to providing effective solutions for patients living with cancer. PIXUVRI is an effective treatment that received standard European marketing authorization in June, and today marks a new step towards achieving Servier’s long term goals. We will ensure that patients will continue to have access to PIXUVRI”, said Eric Falcand, VP, Global Head of Business Development & Licensing at Servier. “We are continuing to strengthen our oncology portfolio through our R&D efforts and strategic alliances.”

#ENDS#

About PIXUVRI (pixantrone)

PIXUVRI is a cytotoxic medicine that works by interfering with the DNA within cells and preventing them from making more copies of DNA. This means that the cancer cells cannot divide and eventually die.3 PIXUVRI is indicated in the European Union as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.3 PIXUVRI is also approved in Iceland, Israel, Liechtenstein, Myanmar, Norway, Pakistan, Russia and Ukraine.

PIXUVRI is mentioned in the ESMO guidelines as an anthracycline-like drug with reduced cardiotoxicity, which demonstrated some efficacy in heavily treated patients.4

More detail is available in the summary of the European public assessment report (EPAR) on the EMA website at www.ema.europa.eu.

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are twelve molecular entities in clinical development in this area, targeting gastro-intestinal and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics and immune targeted therapies, to deliver life-changing medicines to patients.

More information: www.servier.com

Follow us on Social Media: LinkedIn I Facebook I Twitter


1 Cancer Research UK. What is NHL cancer. Available at http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/about/what-is-lymphoma. Last accessed September 2019.
2 World Health Organisation. Globocan 2018. Non-Hodgkin lymphoma. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/34-Non-hodgkin-lymphoma-fact-sheet.pdf. Last accessed September 2019.
3 European Medicines Agency. Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/pixuvri-epar-product-information_en.pdf. Last accessed September 2019.
4 Tilly H et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology (2015). Volume 26 (suppl 5); v116-v125. Available at: http://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma. Last accessed September 2019.

Contact information

Servier Media Relations
Sonia Marques
sonia.marques@servier.com
Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13

Jean-Clément Vergeau
jean-clement.vergeau@servier.com
Tel. +33 (0)1 55 72 46 16 / + 33 (0) 6 79 56 75 96

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Isturisa® Is Now Available as a Medical Treatment for Cushing's Syndrome in Germany16.7.2020 18:00:00 EESTPress release

Cortisol synthesis inhibitor osilodrostat (Isturisa®) is now available in Germany as of July 15, 2020, as a promising new therapy option for medical treatment of adult patients with endogenous Cushing’s syndrome (CS).1,4 Isturisa® was approved by the European Commission on January 9, 2020. The approval of Isturisa® (osilodrostat) is based on the results of the pivotal phase III study, LINC-3, in which the efficacy and safety of osilodrostat in 137 patients with Cushing’s disease were assessed. A significantly higher proportion of patients with Cushing’s disease treated with Isturisa® maintained normal mean urinary free cortisol (mUFC) at the end of the 8‐week randomized withdrawal period (week 34) versus placebo (86% vs 29%). Cortisol level control is the primary objective in the treatment of patients with Cushing’s disease. Thus, the study successfully met its primary and key secondary endpoint.1,3 Moreover, the results showed that osilodrostat resulted in a rapid and sustained reduct

PMI Launches “Our World Is Not an Ashtray” Initiative and Aims to Halve Plastic Litter from Products by 202516.7.2020 17:13:00 EESTPress release

Philip Morris International Inc. (PMI) (NYSE:PM) today launched “Our World Is Not an Ashtray,” a new global initiative to raise awareness and drive a long-term change in behavior and attitudes around cigarette butt littering. The initiative supports PMI’s litter reduction target—described in its Integrated Report 2019—to achieve a 50 percent reduction of the plastic litter from its products by 2025 (vs. 2021 baseline). The initiative, launched on WorldNoAshtray.com, aims to educate the public about the environmental impact of cigarette butt littering and inspire adult smokers to change littering habits. “We seek to make cigarette butt littering socially unacceptable,” said Huub Savelkouls, Chief Sustainability Officer at PMI. “‘Our World Is Not an Ashtray’ is an important initiative in our multipronged approach to addressing this important issue.” To track progress against its goal, PMI is working with three organizations—Litterati, Cortexia, and CARTO—to implement a data-driven approa

European Industry Leaders From Energy, Mobility & Sustainability Join Energy Impact Partners Global Innovation Platform16.7.2020 17:00:00 EESTPress release

Energy Impact Partners (EIP), the global investment platform leading the transition to a sustainable energy future, has announced the formation of a European Coalition to advance new technologies and tackle climate change. EIP works closely with its investors -- more than 25 of the largest, most innovative, and environmentally conscious energy and industrial companies as well as climate-investors -- to develop cutting-edge solutions across four continents through a unique collaborative model. The EIP network collaborates by sharing insights, investing in innovative and transformative businesses, and then amplifying entrepreneurs' growth through dedicated partnerships. “Our proven model is based on collaboration, learning, and sharing -- and it can only thrive with the right partners. We are thrilled to see some of the most innovative European players and AGL, the leading utility in Australia, join our mission as founding members.” - Matthias Dill, CEO & Managing Director Europe for Ene

Andersen Global Continues Caribbean Expansion with Additional Presence in Trinidad and Tobago16.7.2020 16:30:00 EESTPress release

Andersen Global announces an expanded presence in Trinidad and Tobago with collaborating firm, Johnson, Camacho & Singh, adding depth to the organization’s platform as it accelerates its expansion efforts the Caribbean region. Located in Port of Spain, Trinidad, the full-service law firm, is well known throughout the region, with thirteen attorneys covering corporate and commercial law, commercial litigation, property development and conveyancing, oil and gas, mergers and acquisitions, insolvency, and banking and finance. Additionally, the firm is ranked Band 2 for General Business Law in Trinidad and Tobago, Global Ranking by Chambers & Partners. The partners of Johnson, Camacho & Singh are of the view that the collaboration with Andersen Global is the next milestone for the firm as it will allow us to extend beyond the regional market and provide our clients with the resources of a global firm. Senior Partner, Stephen Singh, added, “Expertise and professionalism are important qualiti

Survey: More Than Half of Sustainability Leaders Believe That Consumer Demand for Environmental Action Has Grown During COVID-19, and Many Think They May Lose Customers If They Don’t Meet Commitments16.7.2020 16:05:00 EESTPress release

A recent global survey shows 54 percent of sustainability leaders at apparel and textile brands say they’ve seen their customers’ demands for environmentally sustainable practices and products increase since the beginning of the COVID-19 pandemic, but 59 percent said they believe customers will still continue to prioritize price when making purchases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716005189/en/ Simplified Infographic Covid-19-Survey Highlights (Graphic: Business Wire) The U.S. Cotton Trust Protocol conducted this survey to find how sustainability programs at brands and retailers had changed in a post-COVID world. The survey found that 43% of respondents believe COVID-19 has had a positive impact on investments in sustainability efforts during this period, while 40% believe it has had a negative impact. Likewise, they believe their customers are facing the same struggle between their pocketbooks and the en

USB-IF Publishes USB Device Class Specification for MIDI Devices v2.016.7.2020 16:00:00 EESTPress release

USB Implementers Forum (USB-IF), the support organization for the advancement and adoption of USB technology, today announced an updated USB Device Class Definition for MIDI Devices, Version 2.0 in support of MIDI 2.0 devices. The standard represents an industry-wide effort by the USB-IF, MIDI Manufacturers Association (MMA), and Association of Musical Electronics Industry (AMEI) to provide MIDI users with an expanded MIDI environment connected by USB. “USB-IF is proud to support the MMA and AMEI by publishing an updated USB Device Class Specification for next-generation MIDI devices,” said Jeff Ravencraft, USB-IF President and COO. “USB has been an integral part of the MIDI environment over the past 20 years, and we look forward to seeing innovative new devices that are enabled by this updated specification.” Mike Kent, Project Chair of the USB MIDI class specification and Chairman of the MMA's MIDI 2.0 Working Group, said, "This updated specification delivers many improvements that m

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom